Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma research hub

C4221023 - A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY

This study is looking at new drug combinations for people with a certain type of advanced melanoma that has not responded to previous treatment. It compares two groups of medicines to see which works better at shrinking the cancer.